

**RTA LABORATUVARLARI BİYOLOJİK ÜRÜNLER İLAÇ VE
MAKİNA SANAYİ TİCARET A.Ş.
Financial Report
Unconsolidated
2019 - 2. 3 Monthly Notification**

General Information About Financial Statements

| | |
|---------------------------|--|
| Independent Audit Company | ATA ULUSLARARASI BAĞIMSIZ DENETİM VE SMMM A.Ş. |
| Audit Type | Limited |
| Audit Result | Positive |

ARA DÖNEM FİNANSAL BİLGİLERE İLİŞKİN

SINIRLI DENETİM RAPORU

RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine Sanayi Ticaret Anonim Şirketi

Yönetim Kurulu'na,

Finansal Tablolara İlişkin Rapor

1. RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine Sanayi Ticaret Anonim Şirketi'nin ("Şirket") ekte yer alan 30 Haziran 2019 tarihli finansal durum tablosu ve aynı tarihte sona eren altı aylık dönemine ait kar zarar ve diğer kapsamlı gelir tablosu, özkaynaklar değişim tablosu, nakit akış tablosu ve önemli muhasebe politikalarının özeti ile dipnotlarının sınırlı denetimini yürütmüş bulunuyoruz. Şirket yönetimi, söz konusu ara dönem finansal bilgilerin Türkiye Muhasebe Standartlarına uygun olarak hazırlanmasından ve sunumundan sorumludur. Sorumluluğumuz, yaptığımız sınırlı denetime dayanarak söz konusu ara dönem finansal bilgilere ilişkin bir sonuç bildirmektir.

Sınırlı denetimin kapsamı

2. Yaptığımız sınırlı denetim, Sınırlı Bağımsız Denetim Standardı (SBDS) 2410 "Ara Dönem Finansal Bilgilerin, İşletmenin Yıllık Finansal Tablolarının Bağımsız Denetimini Yürüten Denetçi Tarafından Sınırlı Bağımsız Denetimi"ne uygun olarak yürütülmüştür. Ara dönem finansal bilgilere ilişkin sınırlı denetim, başta finans ve muhasebe konularından sorumlu kişiler olmak üzere ilgili kişilerin sorgulanması ve analitik prosedürler ile diğer sınırlı denetim prosedürlerinin uygulanmasından oluşur. Ara dönem finansal bilgilerin sınırlı denetiminin kapsamı; Bağımsız Denetim Standartları'na uygun olarak yapılan ve amacı finansal tablolar hakkında bir görüş bildirmek olan bağımsız denetimin kapsamına kıyasla önemli ölçüde

dardır. Sonuç olarak ara dönem finansal bilgilerin sınırlı denetimi, denetim şirketinin, bir bağımsız denetimde belirlenebilecek tüm önemli hususlara vakıf olabileceğine ilişkin bir güvence sağlamamaktadır. Bu sebeple, bir bağımsız denetim görüşü bildirmemekteyiz.

Sonuç

3. Sınırlı denetimimize göre, ilişikteki ara dönem finansal bilgilerin, RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine Sanayi Ticaret Anonim Şirketi'nin 30 Haziran 2019 tarihi itibarıyla finansal durumunun, finansal performansının ve aynı tarihte sona eren altı aylık döneme ilişkin nakit akışlarının Türkiye Muhasebe Standartlarına uygun olarak, doğru ve gerçeğe uygun bir görünümünü sağlamadığı kanaatine varmamıza sebep olacak herhangi bir husus dikkatimizi çekmemiştir.

Diğer Husus

4. Şirket'in 31 Aralık 2018 tarihinde sona eren yıla ait Not 2.d'de açıklanan yeniden düzenlemenin etkilerini içermeyen konsolide finansal tablolarının bağımsız denetimi ve 30 Haziran 2018 tarihinde sona eren yıla ait özet konsolide finansal tablolarının sınırlı incelemesi başka bir bağımsız denetim kuruluşu tarafından yapılmıştır. Önceki bağımsız denetim kuruluşu, 31 Aralık 2018 tarihli konsolide finansal tablolar ile ilgili olarak 11 Mart 2019 tarihli bağımsız denetim raporunda olumlu görüş bildirmiştir. Ayrıca 30 Haziran 2018 tarihli konsolide finansal tablolar ile ilgili olarak 17 Ağustos 2018 tarihli sınırlı inceleme raporunda olumlu sonuç bildirmiştir.

30 Haziran 2019 tarihinde sona eren hesap dönemine ait finansal tablolara ilişkin yürüttüğümüz sınırlı denetim kapsamında, 2018 hesap dönemine ait konsolide finansal tabloları değiştirmek için yapılan ve Not 2.d'de açıklanan düzeltmeleri de ayrıca denetlemiş bulunuyoruz. İncelememize göre, söz konusu düzeltmeler finansal tablolara yansıtılmıştır. Söz konusu düzeltmeler dışında, Şirket'in 2018 hesap dönemine ait konsolide finansal tablolarının bağımsız denetimi veya bunlara yönelik herhangi bir prosedürü uygulamak için görevlendirilmediğimizden , bir bütün olarak 2018 hesap dönemine ait finansal tablolara ilişkin bir denetim görüşü veya başka bir güvence vermiyoruz.

ATA Uluslararası Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik A.Ş.

Member Firm of Kreston International

Halil İbrahim Yürüdü

Sorumlu Denetçi

İstanbul, 9 Ağustos 2019

Statement of Financial Position (Balance Sheet)

| | |
|--------------------------------|----------------|
| Presentation Currency | TL |
| Nature of Financial Statements | Unconsolidated |

| | Footnote Reference | Current Period 30.06.2019 | Previous Period 31.12.2018 |
|--|--------------------|------------------------------|-------------------------------|
| Statement of Financial Position (Balance Sheet) | | | |
| Assets [abstract] | | | |
| CURRENT ASSETS | | | |
| Cash and cash equivalents | 5 | 632.905 | 6.140.988 |
| Financial Investments | 6 | 40.988 | 51.376 |
| Trade Receivables | | 7.471.647 | 8.373.266 |
| Trade Receivables Due From Related Parties | 7 | 0 | 1.379.492 |
| Trade Receivables Due From Unrelated Parties | 8 | 7.471.647 | 6.993.774 |
| Other Receivables | | 225.161 | 10.858.132 |
| Other Receivables Due From Related Parties | 7 | 0 | 10.074.277 |
| Other Receivables Due From Unrelated Parties | 10 | 225.161 | 783.855 |
| Inventories | 11 | 3.809.273 | 3.870.859 |
| Prepayments | | 411.366 | 868.433 |
| Prepayments to Unrelated Parties | 14 | 411.366 | 868.433 |
| Current Tax Assets | 13 | 35.102 | 220.814 |
| Other current assets | 12 | 2.249.806 | 2.480.560 |
| SUB-TOTAL | | 14.876.248 | 32.864.428 |
| Total current assets | | 14.876.248 | 32.864.428 |
| NON-CURRENT ASSETS | | | |
| Trade Receivables | | 364.068 | 0 |
| Trade Receivables Due From Unrelated Parties | 8 | 364.068 | 0 |
| Other Receivables | | 2.450 | 2.450 |
| Other Receivables Due From Unrelated Parties | 10 | 2.450 | 2.450 |
| Investments accounted for using equity method | 4 | 22.268.922 | 0 |
| Investment property | 15 | 18.474.558 | 18.600.000 |
| Property, plant and equipment | 16 | 11.901.542 | 11.166.656 |
| Intangible assets and goodwill | | 610.157 | 1.717.613 |
| Goodwill | 3 | 0 | 1.030.700 |
| Other intangible assets | 17 | 610.157 | 686.913 |
| Prepayments | | 1.925.476 | 0 |
| Prepayments to Related Parties | 7 | 0 | 0 |
| Prepayments to Unrelated Parties | 14 | 1.925.476 | 0 |
| Deferred Tax Asset | 28 | 699.562 | 1.289.209 |
| Total non-current assets | | 56.246.735 | 32.775.928 |
| Total assets | | 71.122.983 | 65.640.356 |
| LIABILITIES AND EQUITY | | | |
| CURRENT LIABILITIES | | | |
| Current Borrowings | 9 | 0 | 636.553 |
| Trade Payables | | 2.143.503 | 5.260.011 |
| Trade Payables to Related Parties | 7 | 0 | 356.792 |
| Trade Payables to Unrelated Parties | 8 | 2.143.503 | 4.903.219 |
| Employee Benefit Obligations | 20 | 421.227 | 349.198 |
| Other Payables | | 86.375 | 167.348 |
| Other Payables to Unrelated Parties | 10 | 86.375 | 167.348 |
| Deferred Income Other Than Contract Liabilities | 14 | 79.400 | 64.393 |
| Current tax liabilities, current | 28 | 0 | 0 |
| Current provisions | | 66.166 | 147.694 |
| Current provisions for employee benefits | 19 | 24.056 | 105.584 |
| Other current provisions | 19 | 42.110 | 42.110 |
| SUB-TOTAL | | 2.796.671 | 6.625.197 |
| Total current liabilities | | 2.796.671 | 6.625.197 |
| NON-CURRENT LIABILITIES | | | |
| Other Payables | | 3.086.797 | 0 |
| Other Payables to Related Parties | 10 | 3.086.797 | 0 |
| Non-current provisions | | 295.888 | 329.745 |
| Non-current provisions for employee benefits | 19 | 295.888 | 329.745 |
| Total non-current liabilities | | 3.382.685 | 329.745 |
| Total liabilities | | 6.179.356 | 6.954.942 |
| EQUITY | | | |
| Equity attributable to owners of parent | | 64.943.627 | 59.535.903 |

| | | | |
|--|--------|------------|------------|
| Issued capital | 21.1 | 23.600.000 | 23.600.000 |
| Other Accumulated Comprehensive Income (Loss) that will not be Reclassified in Profit or Loss | | 8.052.190 | 8.161.427 |
| Gains (Losses) on Revaluation and Remeasurement | | 8.083.266 | 8.161.427 |
| Increases (Decreases) on Revaluation of Property, Plant and Equipment | 21.2.1 | 8.109.894 | 8.109.894 |
| Gains (Losses) on Remeasurements of Defined Benefit Plans | 21.2.2 | -26.628 | 51.533 |
| Share of Other Comprehensive Income of Investments Accounted for Using Equity Method that will not be Reclassified to Profit or Loss | 4 | -31.076 | 0 |
| Restricted Reserves Appropriated From Profits | 21.3 | 1.399.707 | 1.399.707 |
| Prior Years' Profits or Losses | 21.4 | 26.405.028 | 24.175.463 |
| Current Period Net Profit Or Loss | | 5.486.702 | 2.199.306 |
| Non-controlling interests | 21.5 | 0 | -850.489 |
| Total equity | | 64.943.627 | 58.685.414 |
| Total Liabilities and Equity | | 71.122.983 | 65.640.356 |

Statement of Profit or Loss and Other Comprehensive Income

| | |
|--------------------------------|----------------|
| Presentation Currency | TL |
| Nature of Financial Statements | Unconsolidated |

| | Footnote Reference | Current Period 01.01.2019 - 30.06.2019 | Previous Period 01.01.2018 - 30.06.2018 | Current Period 3 Months 01.04.2019 - 30.06.2019 | Previous Period 3 Months 01.04.2018 - 30.06.2018 |
|--|--------------------|--|---|--|---|
| Statement of Profit or Loss and Other Comprehensive Income | | | | | |
| PROFIT (LOSS) | | | | | |
| Revenue | 22.1 | 9.098.447 | 10.474.411 | 3.515.890 | 5.050.386 |
| Cost of sales | 22.2 | -6.659.439 | -8.002.856 | -2.912.928 | -4.074.123 |
| GROSS PROFIT (LOSS) FROM COMMERCIAL OPERATIONS | | 2.439.008 | 2.471.555 | 602.962 | 976.263 |
| Revenue from Finance Sector Operations | | 0 | 0 | 0 | 0 |
| Cost of Finance Sector Operations | | 0 | 0 | 0 | 0 |
| GROSS PROFIT (LOSS) FROM FINANCE SECTOR OPERATIONS | | 0 | 0 | 0 | 0 |
| GROSS PROFIT (LOSS) | | 2.439.008 | 2.471.555 | 602.962 | 976.263 |
| General Administrative Expenses | 24.1 | -1.574.983 | -1.396.488 | -700.824 | -398.871 |
| Marketing Expenses | 24.2 | -1.197.431 | -1.872.076 | -513.720 | -894.602 |
| Research and development expense | 24.3 | -1.874.784 | -855.880 | -1.142.435 | 0 |
| Other Income from Operating Activities | 25.1 | 4.505.319 | 2.214.243 | 784.929 | 801.696 |
| Other Expenses from Operating Activities | 25.2 | -2.105.017 | -3.095.904 | 866.773 | -1.704.424 |
| PROFIT (LOSS) FROM OPERATING ACTIVITIES | | 192.112 | -2.534.550 | -102.315 | -1.219.938 |
| Investment Activity Income | 26.1 | 4.710.618 | 1.650.893 | 2.450.649 | 934.922 |
| Investment Activity Expenses | 26.2 | -1.873.489 | -272.755 | -646.195 | -209.964 |
| Share of Profit (Loss) from Investments Accounted for Using Equity Method | 4 | 1.643.274 | 0 | 1.643.274 | 0 |
| PROFIT (LOSS) BEFORE FINANCING INCOME (EXPENSE) | | 4.672.515 | -1.156.412 | 3.345.413 | -494.980 |
| Finance income | 27.1 | 315.457 | 1.217.171 | 159.326 | 937.660 |
| Finance costs | 27.2 | -59.901 | -615.976 | 139.737 | -263.479 |
| PROFIT (LOSS) FROM CONTINUING OPERATIONS, BEFORE TAX | | 4.928.071 | -555.217 | 3.644.476 | 179.201 |
| Tax (Expense) Income, Continuing Operations | | 709.535 | 587.126 | 67.785 | -100.462 |
| Current Period Tax (Expense) Income | 28 | 0 | 0 | 28.635 | 84.967 |
| Deferred Tax (Expense) Income | 28 | 709.535 | 587.126 | 39.150 | -185.429 |
| PROFIT (LOSS) FROM CONTINUING OPERATIONS | | 5.637.606 | 31.909 | 3.712.261 | 78.739 |
| PROFIT (LOSS) | | 5.637.606 | 31.909 | 3.712.261 | 78.739 |
| Profit (loss), attributable to [abstract] | | | | | |
| Non-controlling Interests | 21.5 | 150.904 | -60.158 | 0 | 23.480 |
| Owners of Parent | | 5.486.702 | 92.067 | 3.712.261 | 55.259 |
| Earnings per share [abstract] | | | | | |
| Earnings per share [line items] | | | | | |
| Basic earnings per share | | | | | |
| Diluted Earnings Per Share | | | | | |
| OTHER COMPREHENSIVE INCOME | | | | | |
| Other Comprehensive Income that will not be Reclassified to Profit or Loss | | -78.706 | 25.478 | -84.837 | -122.798 |
| Gains (Losses) on Remeasurements of Defined Benefit Plans | 21.2.2 | -59.538 | 31.848 | -67.202 | -153.497 |
| Share of Other Comprehensive Income of Associates and Joint Ventures Accounted for Using Equity Method that will not be Reclassified to Profit or Loss | | -31.076 | 0 | -31.076 | 0 |
| Gains (Losses) on Remeasurements of Defined Benefit Plans of Associates and Joint Ventures Accounted for Using Equity Method | 4 | -31.076 | 0 | -31.076 | |
| Taxes Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | | 11.908 | -6.370 | 13.441 | 30.699 |
| Deferred Tax (Expense) Income | | 11.908 | -6.370 | 13.441 | 30.699 |
| Other Comprehensive Income That Will Be Reclassified to Profit or Loss | | 0 | 0 | 0 | 0 |
| Exchange Differences on Translation | | 0 | 0 | 0 | 0 |
| Gains (Losses) on Remeasuring or Reclassification Adjustments on Available-for-sale Financial Assets | | 0 | 0 | 0 | 0 |
| Other Comprehensive Income (Loss) Related with Financial Assets Measured at Fair Value through Other Comprehensive Income | | 0 | 0 | 0 | 0 |
| Other Comprehensive Income (Loss) Related with Cash Flow Hedges | | 0 | 0 | 0 | 0 |
| | | | | | |

| | | | | | |
|--|--|-----------|---------|-----------|----------|
| Other Comprehensive Income (Loss) Related with Hedges of Net Investments in Foreign Operations | | 0 | 0 | 0 | 0 |
| Change in Value of Time Value of Options | | 0 | 0 | 0 | 0 |
| Change in Value of Forward Elements of Forward Contracts | | 0 | 0 | 0 | 0 |
| Change in Value of Foreign Currency Basis Spreads | | 0 | 0 | 0 | 0 |
| Share of Other Comprehensive Income of Associates and Joint Ventures Accounted for Using Equity Method that will be Reclassified to Profit or Loss | | 0 | 0 | 0 | 0 |
| Taxes Relating to Components of Other Comprehensive Income that will be Reclassified to Profit or Loss | | 0 | 0 | 0 | 0 |
| OTHER COMPREHENSIVE INCOME (LOSS) | | -78.706 | 25.478 | -84.837 | -122.798 |
| TOTAL COMPREHENSIVE INCOME (LOSS) | | 5.558.900 | 57.387 | 3.627.424 | -44.059 |
| Total Comprehensive Income Attributable to | | | | | |
| Non-controlling Interests | | 150.895 | -57.192 | 0 | 23.507 |
| Owners of Parent | | 5.408.005 | 114.579 | 3.627.424 | -67.566 |

Statement of cash flows (Indirect Method)

| | |
|--------------------------------|----------------|
| Presentation Currency | TL |
| Nature of Financial Statements | Unconsolidated |

| | Footnote Reference | Current Period 01.01.2019 - 30.06.2019 | Previous Period 01.01.2018 - 30.06.2018 |
|---|--------------------|---|--|
| Statement of cash flows (Indirect Method) | | | |
| CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES | | 15.723.038 | 3.436.600 |
| Profit (Loss) | | 5.637.606 | 31.909 |
| Adjustments to Reconcile Profit (Loss) | | -2.828.428 | 254.751 |
| Adjustments for depreciation and amortisation expense | | 841.431 | 758.978 |
| Adjustments for provisions | | -115.385 | -60.917 |
| Adjustments for (Reversal of) Provisions Related with Employee Benefits | 19 | -115.385 | -60.917 |
| Adjustments for Interest (Income) Expenses | | 294.148 | 137.446 |
| Deferred Financial Expense from Credit Purchases | 18 | 511.190 | 590.125 |
| Unearned Financial Income from Credit Sales | 18 | -217.042 | -452.679 |
| Adjustments for Undistributed Profits of Investments Accounted for Using Equity Method | 4 | -1.643.274 | 0 |
| Adjustments for Tax (Income) Expenses | 28 | -721.443 | -580.756 |
| Other adjustments to reconcile profit (loss) | 26 | -1.483.905 | 0 |
| Changes in Working Capital | | 12.913.860 | 4.489.800 |
| Decrease (Increase) in Financial Investments | 6 | 10.388 | -1.827.936 |
| Adjustments for decrease (increase) in trade accounts receivable | 8 | 26.361 | 5.624.523 |
| Adjustments for Decrease (Increase) in Other Receivables Related with Operations | | 11.049.437 | 122.833 |
| Adjustments for decrease (increase) in inventories | 11 | 61.586 | 626.606 |
| Decrease (Increase) in Prepaid Expenses | 14 | -1.468.409 | -401.487 |
| Adjustments for increase (decrease) in trade accounts payable | 8 | -2.899.466 | -843.971 |
| Increase (Decrease) in Employee Benefit Liabilities | 20 | 72.029 | 0 |
| Adjustments for increase (decrease) in other operating payables | | 3.005.824 | 59.141 |
| Increase (Decrease) in Deferred Income Other Than Contract Liabilities | 14 | 15.007 | -47.120 |
| Other Adjustments for Other Increase (Decrease) in Working Capital | | 3.041.103 | 1.177.211 |
| Cash Flows from (used in) Operations | | 15.723.038 | 4.776.460 |
| Income taxes refund (paid) | | | -1.339.860 |
| CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES | | -20.546.938 | -1.907.314 |
| Cash Outflows Arising From Purchase of Shares or Capital Increase of Associates and/or Joint Ventures | | -19.172.819 | 0 |
| Proceeds from sales of property, plant, equipment and intangible assets | | 84.622 | |
| Purchase of Property, Plant, Equipment and Intangible Assets | | -1.458.741 | -1.907.314 |
| Purchase of property, plant and equipment | 16 | -1.376.587 | -1.907.314 |
| Purchase of intangible assets | 17 | -82.154 | 0 |
| CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES | | -684.183 | -511.270 |
| Repayments of borrowings | | -636.553 | -511.270 |
| Loan Repayments | 9 | -636.553 | -511.270 |
| Other inflows (outflows) of cash | 21.2.1 | -47.630 | 0 |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS BEFORE EFFECT OF EXCHANGE RATE CHANGES | | -5.508.083 | 1.018.016 |
| Net increase (decrease) in cash and cash equivalents | | -5.508.083 | 1.018.016 |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | 5 | 6.140.988 | 15.123.565 |
| CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | 5 | 632.905 | 16.141.581 |

[illegible]

[illegible]